We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00130715
First Posted: August 16, 2005
Last Update Posted: March 12, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sanofi
August 15, 2005
August 16, 2005
March 12, 2015
June 1998
Not Provided
Reducing the incidence of bowel obstruction following intestinal resection, and subsequently, reducing the number of re-operations
Reducing the incidence of bowel obstruction following intestinal resection, and subsequently, reducing the number of re-operations.
Complete list of historical versions of study NCT00130715 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery
A Prospective, Randomized, Multicenter, Controlled Evaluation of the Efficacy and Safety of Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery
The purpose of the study is to evaluate the efficacy of Seprafilm in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm occurring within 30 days postoperatively, and the incidence of abdominopelvic abscess within 6 months postoperatively.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
  • Intestinal Obstruction
  • Digestive System Surgical Procedures
Device: Seprafilm Bioresorbable Membrane
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
August 2003
Not Provided

Inclusion Criteria:

  • Patients who were undergoing colon and/or rectal resections and/or adhesiolysis for treatment of bowel obstruction

Exclusion Criteria:

  • Patients with any medical condition or disease where 5-year survival was not expected
  • Patients undergoing laparoscopy
  • Patients undergoing surgery for treatment of acute abdominal trauma
  • Patients with an abscess (abdominal or pelvic) present during the initial surgery
  • Patients with a history of pulmonary embolus or deep vein thrombosis (DVT) within 1 year of surgery
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Germany,   Netherlands,   United Kingdom,   United States
 
 
NCT00130715
SF97-0601
Not Provided
Not Provided
Not Provided
Not Provided
Genzyme, a Sanofi Company
Not Provided
Not Provided
Sanofi
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP